AAV serotype 9

GPTKB entity

Properties (52)
Predicate Object
gptkbp:instanceOf gptkb:Research_Institute
gptkbp:canBe therapeutic genes
gptkbp:hasEconomy neurons
gptkbp:hasProductLine recombinant DNA technology
gptkbp:hasRelatedPatent cardiovascular diseases
gptkbp:hasResearchFocus gene editing
gptkbp:hasSibling 4.7 kb
https://www.w3.org/2000/01/rdf-schema#label AAV serotype 9
gptkbp:isAttendedBy animal models
intravenous injection
gptkbp:isCharacterizedBy low immunogenicity
gptkbp:isCompatibleWith CRISPR technology
gptkbp:isConsidered a promising vector for CNS delivery
clinical applications in humans
delivering large genes
therapeutic gene delivery strategies
treatment of inherited disorders
gptkbp:isEvaluatedBy safety and efficacy
its effectiveness in various tissues
gptkbp:isFacilitatedBy gene expression in target cells
gptkbp:isInvolvedIn retinal diseases
gptkbp:isKnownFor a non-pathogenic virus
high transduction efficiency
its ability to integrate into host genome.
skeletal muscle cells
tropism for the central nervous system
gptkbp:isNotedFor long-term expression of transgenes
gptkbp:isPartOf biomedical research initiatives
gene delivery systems
AAV vector system
advanced gene therapy techniques
gene therapy protocols
innovative therapeutic approaches
other AAV serotypes
therapeutic applications of AAVs
vector development strategies
gptkbp:isStudiedIn cancer therapy
neurological disorders
clinical applications for rare diseases
its ability to cross the blood-brain barrier
its potential in treating genetic disorders
gptkbp:isUsedBy muscular dystrophy
gptkbp:isUsedFor neurodegenerative diseases
gptkbp:isUsedIn gene therapy
vaccine development
gptkbp:isUtilizedFor gene function
treatment of spinal muscular atrophy
its role in gene therapy delivery mechanisms
its use in ocular gene therapy
gptkbp:isUtilizedIn clinical trials
preclinical studies
gptkbp:isValuedFor AAV2